Evidence map›Paper›PMID 25386066›Full record

ReviewWorld journal of gastroenterology2014

Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.

Rafael Tojo, Adolfo Suárez, Marta G Clemente, Clara G de los Reyes-Gavilán, Abelardo Margolles, Miguel Gueimonde, Patricia Ruas-Madiedo

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03403907 (The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients), which is not on this map. Cited by 249 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
249citing papers in PubMed, 7 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03403907 nacompletednot on this map

The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients

TypeinterventionalSponsorMaría Gómez EguílazRan2014 to 2015Enrolled45ConditionsEpilepsy, Epilepsy IntractableArmsProbiotic
3 · Its place in the literature

Who cites it

249 citing papers in PubMed, 7 syntheses or guidelines pooled it, 508 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.Computational and mathematical methods in medicine · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Health Benefits ofNutrients · 2019
    Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

189 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rafael TojoRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Adolfo SuárezRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Marta G ClementeRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Clara G de los Reyes-GavilánRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Abelardo MargollesRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Miguel GueimondeRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Patricia Ruas-MadiedoRafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Hospital Universitario De Cabueñes · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition (dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases (inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract (e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.

Indexed as

Health StatusMicrobiotaDysbiosisHomeostasisHost-Pathogen InteractionsHumansIntestinal DiseasesIntestinesLiver DiseasesLung DiseasesProbioticsRisk FactorsBifidobacteriumColorectal cancerDysbiosisFunctional foodsInflammatory bowel diseaseIntestinal microbiotaIrritable bowel syndromeLiver diseaseProbioticsRespiratory disease

Identifiers

PMID25386066
PMCPMC4223251
OpenAlexW1995056069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.